바로가기메뉴

본문 바로가기 주메뉴 바로가기

logo

ISSN : 3022-6805

Article Contents

Prev Next
e-Submission

Vol.11 No.2

Citation Share

Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis)

CELLMED / CELLMED, (P)3022-6805; (E)3022-6791
2021, v.11 no.2, pp.9-9
https://doi.org/10.5667/CellMed.2021.0009
Mohd Abdul Kayum (Department of Moalajat, National Research Institute of Unani Medicine for Skin Disorders)
Ifra Abdul Qaiyyum (Department of Moalajat, National Research Institute of Unani Medicine for Skin Disorders)
Arzeena Jabeen (Department of Moalajat, National Research Institute of Unani Medicine for Skin Disorders)
Mohammad Nawab (Department of Moalajat, National Research Institute of Unani Medicine for Skin Disorders)
Mohd, A. K. , Ifra, A. Q. , Arzeena, J. , & Mohammad, N. (2021). Evaluating Clinical Efficacy and Safety of A Unani Formulation in the Management of Nazla-i-Muzmin (Chronic Rhinosinusitis). CELLMED, 11(2), 9-9, https://doi.org/10.5667/CellMed.2021.0009

Abstract

Nazla-i-muzmin (Chronic rhinosinusitis) is one of the commonest diseases prevalent all around the world. In India one in eight Indian suffers from this ailment. The current medical management and surgical intervention do not provide complete cure as a result there is a need to search a better alternative drug. The main objective of this study was to evaluate the safety and efficacy of a Unani formulation in the management of chronic rhinosinusitis. This study was designed as a randomised, controlled, parallel group and open label clinical study. It was carried out in 60 participants (30 participants in each group) of chronic rhinosinusitis aged between 18-65 years of either sex. The participants were enrolled based on the symptoms rhinorrhoea, sneezing, facial pain, nasal blockage, post nasal drip and thick nasal discharge. The participants of the test group was treated with a Unani formulation (9 gm) whereas Levocetrizine (10mg) was given to the participants of the control group once at night. In this study the average age of the participants was 30.36 (±10.20) years and 32.63 (±10.97) years in the control and test groups respectively with an average chronicity of 31.26 (± 43.46) months in the control group and 23.86 ± 39.4 months in the test group. The Unani formulation was found effective in reducing rhinorrhoea, sneezing, facial pain, nasal obstruction, post nasal discharge and thick nasal discharge. The snot score at post treatment comparing to the baseline was reduced to 2.1 and 2.0 in the test and control groups respectively. The Unani formulation improved the symptoms of chronic rhinosinusitis in the test group due to the possible action of the ingredients having, deobstruent, anti-inflammatory, concoctive, analgesic, expectorants and antimicrobial activities. It was concluded that the outcome of the study showed the successful management of chronic rhino-sinusitis. The formulation was well tolerated and showed no adverse effect.

keywords
deobstruent, nazla-i-muzmin, rhino-sinusitis, sneezing, Unani formulation

Reference

1.

Bita A, Rosu A, Calina D, et al. An alternative treatment for Candida infections with Nigella sativa extracts, European Journal of Hospital Pharmacy: Science and Practice, 2012; 19:162.

2.

Adams PF, Marano MA. Current estimates from the national health interview survey, 1994. Vital and health statistics. Series 10, Data from the National Health Survey, 1995; 193 (1):1-260.

3.

Anonymous. U.S census bureau, International data base. USA; 2004.

4.

Anonymous. Ikseer Azam, YNM; 515.

5.

Anonymous. Standardization of Single Drug of Unani medicine, (New Delhi, India: CCRUM), pp.196-200, 1992.

6.

Anonymous. The Unani Pharmacopoeia of India: Ministry of Health & family Welfare, Dept. of AYUSH, New Delhi, 2007; 1(1): 42-3

7.

Benninger SM. Adult chronic rhinosinusitis: Definitions, Diagnosis, Epidemiology, and Pathophysiology, Otolaryngology-Head and Neck Surgery, 2003; 129 (3): S1-S32.

8.

Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine, McGraw Hill, 2001.

9.

Chaturvedi A, Grewal DS. A Cross-Sectional Study on Demographic and Clinical Profile of Chronic Rhinosinusitis (CRS) Patients in a Tertiary Care Hospital. Galore International Journal of Health Sciences and Research, 2020; 5 (1):17-9.

10.

Dar AK, Lone AH. Demographic Study of Sinusitis in Patients Visiting Govt: Unani Hospital Srinagar and Ayush Centres in Kashmir, Medical Journal of Islamic World Academy of Sciences, 2013; 109 (893):1-4

11.

Ghulam Nabi Munshi. Makhzanul Mufradat wa Murakkabat. (New Delhi, India; CCRUM), pp.100, 2007

12.

Hair PI, Scott LJ. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies, Drugs, 2006; 66(7):973-96. doi: 10.2165/00003495-200666070-00017.

13.

Hakeem M. Bustanul Mufradat. (New Delhi, India: Idara Kitabul Shifa), 2002, pp. 267, 268, 384, 385, 432, 433, 476, 477

14.

Hall IS, Colman HB. Disease of Nose Throat and Ear. 2nd ed. (Edinburgh, UK: Longman Group Ltd), pp. 61-8, 223-8, 1981

15.

Hodgson TA, Cohen AJ. Medical expenditures for major diseases, 1995, Health Care Financing Review, 1999; 21(2):119

16.

Ibn Baitar. Al-Jamiul Mufradatul Advia. wa al-Aghziya, (Urdu translation CCRUM). III volume, (New Delhi, India: Ministry of Health and Family Welfare, Govt. of India.), pp.271-275, 1999

17.

Ibn Baitar. Al-Jamiul Mufradatul Advia. wa al-Aghziya. (Urdu translation CCRUM), (New Delhi, India: Ministry of Health and Family Welfare, Govt. of India.), pp.248-249, 186, 187, 330, 331, 1999

18.

Kabīruddīn HM. Makhzan al-Mufradāt. (New Delhi, India:Ejaz Publishing House), pp.460-1, YNM

19.

Mihail F. Herbal, traditional and alternative remedies, In Common Cold, pp. 309-347, 2009

20.

Ozaki Y, Soedigdo S, Wattimena YR and Suganda AG. Antiinflammatory effect of mace, aril of Myristica fragrans Houtt. and its active principles, Jpn J Pharmacol, 1989; 49(2): 155-63.

21.

Ray NF, Baraniuk JN, Thamer M, Rinehart CS, Gergen PJ, Kaliner M, Josephs S, Pung YH. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders, Journal of Allergy and Clinical Immunology, 1999; 103 (3):408-14.

22.

Schlossberg D. Infections of the Head and Neck. (New York, USA; Springer). pp. 81-87, 1987

23.

Seys SF, et al. Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The my Sinusitis Coach project by EUFOREA, Allergy, 2020; 75(11):2867-78.

24.

Shamshuddin IQ. Tibb-i-Nabvi. (Al Darul Salfia Mumbai), pp. 553-6, 2008

25.

Tembhurne, SV, Feroz, S, More, BH, & Sakarkar, DM. A review on therapeutic potential of Nigella sativa (kalonji)seeds, Journal of Medicinal Plants Research, 2014; 8(3), 167-177.

CELLMED

e-Submission OA Policy